Schizophrenia.com

Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults

jamesbond April 2, 2020, 12:25pm 1

1 Like

Topic		Replies	Views	Activity
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations News	0	279	April 28, 2022
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression News	0	239	February 22, 2021
Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia News	6	522	March 23, 2020
(Iti-007/lumateperone) Intra-Cellular Therapies stock soars 38% premarket after FDA approves News	32	838	December 24, 2019
Intra-Cellular Therapies Announces Presentation of Lumateperone Long-term Open Label Safety Study at the 2019 Congress of the Schizophrenia International Research Society News	1	303	April 9, 2019